SCHEMBL1079634

SCHEMBL1079634

O=C1Nc2ccc(Cl)cc2C(/C=C/C2CC2)(C(F)(F)F)N1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 2/20 0.45
CYP46A1 Q9Y6A2 6/20 0.42
HTR2A P28223 2/20 0.42
NR1I2 O75469 1/20 0.42
NR3C1 P04150 1/20 0.42
PGR P06401 1/20 0.42
ADRB1 P08588 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
MAPT P10636 1/20 0.42
CNR1 P21554 1/20 0.42
SLC6A2 P23975 1/20 0.42
HTR2C P28335 1/20 0.42
MAPK1 P28482 1/20 0.42
AGTR1 P30556 1/20 0.42
CCKBR P32239 1/20 0.42
PPARG P37231 1/20 0.42
OPRK1 P41145 1/20 0.42
SLC6A3 Q01959 1/20 0.42
PDE4D Q08499 1/20 0.42
PDE3A Q14432 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4088810 1.00 PDE7A (0.45) PDE7ACYP46A1HTR2ANR1I2NR3C1
SCHEMBL1046528 1.00 PDE7A (0.45) PDE7ACYP46A1HTR2ANR1I2NR3C1
SCHEMBL29393057 1.00 PDE7A (0.45) PDE7ACYP46A1HTR2ANR1I2NR3C1
SCHEMBL14001649 0.81 CYP46A1 (0.43) PDE7ACYP46A1HTR2AADRA2CTACR2
SCHEMBL6905795 0.81 PDE7A (0.48) PDE7ACYP46A1HTR2ANR1I2NR3C1
SCHEMBL6905802 0.81 PDE7A (0.48) PDE7ACYP46A1HTR2ANR1I2NR3C1
SCHEMBL6905798 0.81 PDE7A (0.48) PDE7ACYP46A1HTR2ANR1I2NR3C1
SCHEMBL7237516 0.80 ADRA2C (0.53) HTR2AADRA2CTACR2ADRA1DPTH1R
SCHEMBL3496644 0.80 ADRA2C (0.53) HTR2AADRA2CTACR2ADRA1DPTH1R
SCHEMBL14439926 0.78 PDE7A (0.32) PDE7ACYP46A1HTR2AADRA2CTACR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872004-B2 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. (JP) 2011-01-18 US disclosed
US-20080207618-A1 6- (Heterocyclyl-substituted Benzyl) -4-Oxoquinoline Compound and Use Thereof as HIV Integrase Inhibitor JAPAN TOBACCO INC. (JP) 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207618-A1 6- (Heterocyclyl-substituted Benzyl) -4-Oxoquinoline Compound and Use Thereof as HIV Integrase Inhibitor CDK6, INTS6, TYMP PDE7A 838/4885CYP46A1 835/4885HTR2A 3863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.